Evidence map›Paper›PMID 41577679›Full record

ArticleNPJ vaccines2026

Recombinant vaccinia vectored ASFV vaccine enhances swine survival against genotype II challenge.

Lanlan Dong, Nan Gao, Renqiang Liu, Kangli Cao, Ai Xia, Tianhan Yang, Xinghao Pan, Cuisong Zhu, Ziling Zhang, Dongming Zhao and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lanlan Dong *Institutes of Biomedical Sciences & Zhongshan Hospital, Fudan University, Shanghai, PR China.
Nan Gao *Department of Gastroenterology, Shanghai Institute of Pancreatic Diseases, National Key Laboratory of Immunity and Inflammation, Changhai Clinical Research Unit, Changhai Hospital, Naval Medical University, Shanghai, PR China.
Renqiang Liu *State Key Laboratory for Animal Disease Control and Prevention, National African Swine Fever Para-reference Laboratory, National High Containment Facilities for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, PR China.
Kangli CaoInstitutes of Biomedical Sciences & Zhongshan Hospital, Fudan University, Shanghai, PR China.
Ai XiaInstitutes of Biomedical Sciences & Zhongshan Hospital, Fudan University, Shanghai, PR China.
Tianhan YangShanghai Public Health Clinical Center, Fudan University, Shanghai, PR China.
Xinghao PanDepartment of Medicine, Lady Davis Institute-Jewish General Hospital, McGill University, Montreal, QC, Canada.
Cuisong ZhuShanghai Public Health Clinical Center, Fudan University, Shanghai, PR China.
Ziling ZhangInstitutes of Biomedical Sciences & Zhongshan Hospital, Fudan University, Shanghai, PR China.
Dongming ZhaoState Key Laboratory for Animal Disease Control and Prevention, National African Swine Fever Para-reference Laboratory, National High Containment Facilities for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, PR China. zhaodongming@caas.cn.
Chen ZhaoShanghai Public Health Clinical Center, Fudan University, Shanghai, PR China. chen_zhao72@163.com.
Xiaoyan ZhangInstitutes of Biomedical Sciences & Zhongshan Hospital, Fudan University, Shanghai, PR China. zhangxiaoyan@fudan.edu.cn.
Jianqing XuInstitutes of Biomedical Sciences & Zhongshan Hospital, Fudan University, Shanghai, PR China. xujianqing@fudan.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The African Swine Fever Virus (ASFV) poses a major threat to global livestock production by infecting both domestic and wild pigs, causing significant economic loss. Despite promising protective results observed with live attenuated viruses, the safety concern blocked its extensive application. In this study, we developed a novel vaccine combining two recombinant vaccinia viruses-rTTV-D-A and rTTV-K-J-that together express eight ASFV genes, including EP402R (CD2v), B646L (p72), B602L (pB602L), D117L (p17), H240R (pH240R), B438L (p49), E183L (p54), CP204L (p30), and a synthetic T antigen composed of conserved T cell epitopes from multiple ASFV proteins, aiming to induce both humoral and T-cell immune responses against different viral antigens. After demonstrating that this vaccine induced antigen-specific humoral and cellular responses in both mice and swine, its protective efficacy in swine was examined using a lethal challenge model. The vaccinated pigs showed a promising protection against the lethal challenge of a virulent genotype II ASFV strain (100 HAD

Identifiers

PMID41577679
PMCPMC12932654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.